REPLIMUNE GROUP, INC. Operating Lease, Liability, Current
REPLIMUNE GROUP, INC. (REPL) had Operating Lease, Liability, Current of $1.14 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability, Current $1.14M.
- 2026-03-31: Operating Lease, Liability, Current $1.16M.
- 2025-12-31: Operating Lease, Liability, Current $1.21M.
- 2025-09-30: Operating Lease, Liability, Current $1.21M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $1.14M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $1.16M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $1.21M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $1.21M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.22M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.18M 10-K · filed 2026-06-29 |
| 2024-12-31 | $1.16M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $1.20M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.16M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.16M 10-K · filed 2025-05-22 |
| 2023-12-31 | $1.16M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $1.14M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.14M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.12M 10-K · filed 2024-05-16 |
| 2022-12-31 | $1.04M 10-Q · filed 2023-02-09 |
| 2022-09-30 | $1.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.04M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.07M 10-K · filed 2023-05-18 |
| 2021-12-31 | $1.07M 10-Q · filed 2022-02-03 |
| 2021-09-30 | $967.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $975.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $970.00K 10-K · filed 2022-05-19 |
| 2020-12-31 | $965.00K 10-Q · filed 2021-02-04 |
| 2020-09-30 | $896.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $830.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $873.00K 10-K · filed 2021-05-20 |
| 2019-12-31 | $1.01M 10-Q · filed 2020-02-13 |
| 2019-09-30 | $631.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $394.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |